Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 6 , Pages 583-594 , June 2010

Double-Blind Maintenance Safety and Effectiveness Findings From the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study

  • Robert L. Findling, M.D.

      Affiliations

    • Case Western Reserve University
    • Corresponding Author InformationCorrespondence to Robert L Findling, M.D., 10524 Euclid Avenue Suite 1155A, Cleveland OH 44106
    • ,
  • Jacqueline L. Johnson, Dr.P.H.

      Affiliations

    • University of North Carolina at Chapel Hill
    • ,
  • Jon McClellan, M.D.

      Affiliations

    • University of Washington
    • ,
  • Jean A. Frazier, M.D.

      Affiliations

    • UMASS Medical School
    • Cambridge Health Alliance, Harvard Medical School
    • ,
  • Benedetto Vitiello, M.D.

      Affiliations

    • National Institute of Mental Health
    • ,
  • Robert M. Hamer, Ph.D.

      Affiliations

    • University of North Carolina at Chapel Hill
    • ,
  • Jeffrey A. Lieberman, M.D.

      Affiliations

    • Columbia University
    • University of North Carolina at Chapel Hill
    • ,
  • Louise Ritz, M.B.A.

      Affiliations

    • National Institute of Neurological Disorders and Stroke
    • ,
  • Nora K. McNamara, M.D.

      Affiliations

    • Case Western Reserve University
    • ,
  • Jacqui Lingler, B.S.

      Affiliations

    • Case Western Reserve University
    • ,
  • Stefanie Hlastala, Ph.D.

      Affiliations

    • University of Washington
    • ,
  • Leslie Pierson, M.P.H.

      Affiliations

    • Division of Child Psychiatry, Seattle Children's Hospital
    • ,
  • Madeline Puglia, B.A.

      Affiliations

    • University of North Carolina at Chapel Hill
    • ,
  • Ann E. Maloney, M.D.

      Affiliations

    • Maine Medical Center Research Institute
    • University of North Carolina at Chapel Hill
    • ,
  • Emily Michael Kaufman, M.A.

      Affiliations

    • Massachusetts School of Professional Psychology
    • Cambridge Health Alliance, Harvard Medical School
    • ,
  • Nancy Noyes, P.M.H.-N.P.

      Affiliations

    • Maine Medical Center Research Institute
    • Cambridge Health Alliance, Harvard Medical School
    • ,
  • Linmarie Sikich, M.D.

      Affiliations

    • University of North Carolina at Chapel Hill

,Accepted 24 March 2010.

References 

  1. American Academy of Child and Adolescent Psychiatry. Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry. 2001;40(suppl):4S–23S
  2. Frazier JA, McClellan J, Findling RL, et al. Treatment of Early-Onset Schizophrenia Spectrum disorders (TEOSS): demographic and clinical characteristics. J Am Acad Child Adolesc Psychiatry. 2007;46:979–988
  3. Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–1431
  4. Johnsen E, Jørgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry. 2008;8:31
  5. McClellan J, Sikich L, Findling RL, et al. Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2007;46:969–978
  6. Kay SR, Fiszbein A, Opler LA. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:262–276
  7. National Institute of Mental Health. Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull. 1985;21:765–770
  8. Overall JE, Pfefferbaum B. The brief psychiatric rating scale for children. Psychopharmacol Bull. 1982;18:10–16
  9. Hodges K. Child and Adolescent Functional Assessment Scale. Ypsilanti: Department of Psychology, Eastern Michigan University; 1995;
  10. Kalachnik JE. Standardized Monitoring for Psychopharmacologic Medication Side Effects (Manual for the Monitoring of Side Effects Scale (MOSES)). Columbia: University of South Carolina, School of Medicine; 2001;
  11. Simpson GM, Angus JWS. A rating scale for extrapyramidal effects. Acta Psychiatr Scand. 1970;212:111–199
  12. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989;154:672–676
  13. Centers for Disease Control and Prevention (CDC), National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2000;http://www.cdc.gov/growthcharts/
  14. Lieberman JA, Stroup TS, McEvoy JP, et al. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–1223
  15. Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–1087
  16. Kahn RS, Fleischhacker WW, Boter H, et al. EUFEST Study Group Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371:1085–1097
  17. McEvoy JP, Lieberman JA, Perkins DO, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1050–1060

 This article can be used to obtain continuing medical education (CME) category 1 credit at jaacap.org.

 This study was supported by National Institute of Mental Health grants MH-61355 (Dr. Findling) to Case Western Reserve University, MH-61464 (Dr. McClellan) to the University of Washington, MH-62726 (Dr. Frazier) to Harvard Medical School, and MH-61528 (Dr. Sikich) to the University of North Carolina. Drs. Sikich (K23 MH- 01802) and Hlastala (K23 MH70570) were also supported by National Institutes of Health career development awards. The research was conducted in National Institutes of Health-supported Clinical Research Centers at Seattle Children's Hospital, University of Washington (M01-RR-00037), and the University of North Carolina at Chapel Hill (M01-RR00046 and U54RR024383).

 Disclosure: Dr. Findling receives or has received research support, served as a consultant for, and/or served on the speakers' bureau for Abbott, Addrenex, AstraZeneca, Biovail, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Johnson and Johnson, KemPharm, Eli Lilly and Company, Lundbeck, Neuropharm, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Sepracore, Shire, Solvay, Supernus Pharmaceuticals, Validus, and Wyeth. Dr. Frazier receives research funding from or participates in clinical trials with Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Johnson and Johnson, Neuropharm, Otsuka America Pharmaceutical, and Pfizer. Dr. Hamer, in the previous 3 years, received or has receives research support, served as a consultant for and served on a data safety monitoring board/internal displacement monitoring center for Acadia, Allergan, Alpharma, AstraZeneca, Cenerx, Corcept, EnabledMD, Epix, Johnson and Johnson, Novartis, Pepper-Hamilton, Pfizer, SAS Institute, Schwartz, Solvay, Sanofi-Aventis, Takeda, Winston-Strawn (a lawsuit involving Forest, Lundbeck, Sun, Caraco), and Wyeth. He and/or his wife own stock in Bristol-Myers Squibb, Amgen, Eli Lilly and Company, Genentech, Proctor and Gamble, and Sepracor. His wife is retired from Bristol-Myers Squibb. Dr. Liberman serves on the advisory board of Bioline, GlaxoSmithKline, Intracellular Therapies, Eli Lilly and Company, Psychogenics, and Wyeth. He does not receive financial compensation or salary support for his participating as an advisor, except for Intracellular Therapies. He receives grant support from Allon, Forest Labs, Merck, and Pfizer. He holds a patent from Repligen. Dr. Sikick receives research funding or participates in clinical trials with Janssen, Pfizer, Bristol-Myers Squibb, Neuropharm, Curemark, and Seaside Pharmaceuticals. She has received software for a computer intervention in schizophrenia from Posit Science. In the past, Dr. Sikich received research funding from Eli Lilly and Company, Janssen, Pfizer, Otsuka, and AstraZeneca. She has served as a consultant for Sanofi Aventis and ABT Associates. Drs. Johnson, McClellan, Vitiello, McNamara, Hlastala, and Maloney, and Ms. Ritz, Ms. Lingler, Ms. Pierson, Ms. Puglia, Ms. Michael Kaufman, and Ms. Noyes report no biomedical financial interests or potential conflicts of interest.

PII: S0890-8567(10)00294-7

doi: 10.1016/j.jaac.2010.03.013

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 49, Issue 6 , Pages 583-594 , June 2010

Article Tools

* Image Usage & Resolution